- Home
- CGO vs VRCA Comparison
CGO vs VRCA Comparison
Compare CGO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | VRCA |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.9M | 112.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CGO | VRCA |
|---|---|---|
| Price | $12.32 | $5.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 34.7K | ★ 149.0K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,829,000.00 |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $7.90 | $3.28 |
| 52 Week High | $10.93 | $9.82 |
Technical Indicators
Market Signals| Indicator | CGO | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 30.59 |
| Support Level | $12.05 | $5.41 |
| Resistance Level | $12.55 | $7.15 |
| Average True Range (ATR) | 0.16 | 0.43 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 34.52 | 10.91 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.